BACKGROUND: Intravenous prostanoids (epoprostenol and treprostinil) are effective therapies for pulmonary arterial hypertension but carry a risk of catheter-related bloodstream infection (CR-BSI). Prevention of CR-BSI during long-term use of indwelling central venous catheters is important. OBJECTIVE: To evaluate whether using a closed-hub system and waterproofing catheter hub connections reduces the rate of CR-BSI per 1,000 catheter-days. DESIGN: Single-center open observational study (January 2003-December 2008). PATIENTS: Pediatric patients with pulmonary arterial hypertension who received intravenous prostanoids. METHODS: In July 2007, CR-BSI preventive measures were implemented, including the use of a closed-hub system and the waterproofing of catheter hub connections during showering. Rates of CR-BSI before and after implementing preventive measures were compared with respect to medication administered and type of bacterial infection. RESULTS: Fifty patients received intravenous prostanoid therapy for a total of 41,840 catheter-days. The rate of CR-BSI during the study period was 0.51 infections per 1,000 catheter-days for epoprostenol and 1.38 infections per 1,000 catheter-days for treprostinil, which differed significantly (P < .01). CR-BSIs caused by gram-negative pathogens occurred more frequently with treprostinil than with epoprostenol (0.91 infections per 1,000 catheter-days vs 0.08 infections per 1,000 catheter-days; P < .01). Patients treated with treprostinil after the implemented changes had a significant decrease in CR-BSI rate (1.95 infections per 1,000 catheter-days vs 0.19 infections per 1,000 catheter-days; P < .01). CONCLUSION: The closed-hub system and the maintenance of dry catheter hub connections significantly reduced the incidence of CR-BSI (particularly infections caused by gram-negative pathogens) in patients receiving intravenous treprostinil.
BACKGROUND: Intravenous prostanoids (epoprostenol and treprostinil) are effective therapies for pulmonary arterial hypertension but carry a risk of catheter-related bloodstream infection (CR-BSI). Prevention of CR-BSI during long-term use of indwelling central venous catheters is important. OBJECTIVE: To evaluate whether using a closed-hub system and waterproofing catheter hub connections reduces the rate of CR-BSI per 1,000 catheter-days. DESIGN: Single-center open observational study (January 2003-December 2008). PATIENTS: Pediatric patients with pulmonary arterial hypertension who received intravenous prostanoids. METHODS: In July 2007, CR-BSI preventive measures were implemented, including the use of a closed-hub system and the waterproofing of catheter hub connections during showering. Rates of CR-BSI before and after implementing preventive measures were compared with respect to medication administered and type of bacterial infection. RESULTS: Fifty patients received intravenous prostanoid therapy for a total of 41,840 catheter-days. The rate of CR-BSI during the study period was 0.51 infections per 1,000 catheter-days for epoprostenol and 1.38 infections per 1,000 catheter-days for treprostinil, which differed significantly (P < .01). CR-BSIs caused by gram-negative pathogens occurred more frequently with treprostinil than with epoprostenol (0.91 infections per 1,000 catheter-days vs 0.08 infections per 1,000 catheter-days; P < .01). Patients treated with treprostinil after the implemented changes had a significant decrease in CR-BSI rate (1.95 infections per 1,000 catheter-days vs 0.19 infections per 1,000 catheter-days; P < .01). CONCLUSION: The closed-hub system and the maintenance of dry catheter hub connections significantly reduced the incidence of CR-BSI (particularly infections caused by gram-negative pathogens) in patients receiving intravenous treprostinil.
Authors: Jonathan R Edwards; Kelly D Peterson; Mary L Andrus; James S Tolson; Joy S Goulding; Margaret A Dudeck; Randy B Mincey; Daniel A Pollock; Teresa C Horan Journal: Am J Infect Control Date: 2007-06 Impact factor: 2.918
Authors: Mark E Rupp; Lee A Sholtz; Dawn R Jourdan; Nedra D Marion; Laura K Tyner; Paul D Fey; Peter C Iwen; James R Anderson Journal: Clin Infect Dis Date: 2007-04-16 Impact factor: 9.079
Authors: Victor F Tapson; Mardi Gomberg-Maitland; Vallerie V McLaughlin; Raymond L Benza; Allison C Widlitz; Abigail Krichman; Robyn J Barst Journal: Chest Date: 2006-03 Impact factor: 9.410
Authors: Naomi P O'Grady; Mary Alexander; Lillian A Burns; E Patchen Dellinger; Jeffrey Garland; Stephen O Heard; Pamela A Lipsett; Henry Masur; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne G Randolph; Mark E Rupp; Sanjay Saint Journal: Clin Infect Dis Date: 2011-05 Impact factor: 9.079
Authors: Naomi P O'Grady; Mary Alexander; Lillian A Burns; E Patchen Dellinger; Jeffrey Garland; Stephen O Heard; Pamela A Lipsett; Henry Masur; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne G Randolph; Mark E Rupp; Sanjay Saint Journal: Clin Infect Dis Date: 2011-04-01 Impact factor: 9.079
Authors: David B Frank; Matthew A Crystal; David L S Morales; Ken Gerald; Brian D Hanna; George B Mallory; Joseph W Rossano Journal: Pulm Circ Date: 2015-06 Impact factor: 3.017
Authors: D Sammut; C A Elliot; D G Kiely; I J Armstrong; L Martin; J Wilkinson; P Sephton; J Jones; N Hamilton; J Hurdman; E McLellan; I Sabroe; R Condliffe Journal: Eur J Clin Microbiol Infect Dis Date: 2013-02-07 Impact factor: 3.267
Authors: Natalie Kitterman; Abby Poms; Dave P Miller; Sandra Lombardi; Harrison W Farber; Robyn J Barst Journal: Mayo Clin Proc Date: 2012-08-09 Impact factor: 7.616